Liposomal Irinotecan and Apatinib in ES-SCLC

NCT06749691 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer Extensive Stage

Interventions

DRUG: Liposomal Irinotecan and Apatinib

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University